Benidipine in Hypertensive and/or Chronic Coronary Syndrome Patients

• Benidipine is a dihydropyridine calcium channel blocker used in the treatment of hypertension and angina pectoris. There are currently no large-scale observational studies in these patient groups in Turkey.
• There is no record of benidipine in clinicaltrials.gov, which is an important database especially for the registration of drug and interventional studies.
• Therefore, it will be extremely important to include this study in clinicaltrials.gov and to evaluate the clinical efficacy of Bendipine in patients with hypertensive and/or angina pectoris in 7 geographical regions of Turkey.

Inclusion criteria

• Patients with hypertension and/or angina pectoris on the background of chronic coronary syndrome who have been receiving Benidipine treatment for at least 1 month and will continue to receive Benidipine treatment
• Male or female outpatients, 18-80 years of age
• Patients with mild to moderate essential hypertension who have been receiving or will continue Benidipine treatment for at least 1 month
• Outpatients with clinically stable angina pectoris and patients who have been receiving or will continue Benidipine treatment for at least 1 month
• Those who signed the written informed consent form

Exclusion criteria

• Patients with secondary hypertension
• Emergency hypertensive patients
• Having to take other medications during the study that may affect blood pressure
• Allergic to DHP calcium antagonists
• Evidence of decompensated congestive heart failure, unstable angina or severe arrhythmia
• Severe renal or hepatic dysfunction
• Pregnant or lactating women
• Participation in other clinical trials within 3 months prior to this study
• Patients who did not sign the consent form of the study